News
UBS Maintains Buy on Biohaven, Raises Price Target to $60
23 Apr 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Biohaven
18 Apr 24
News, Reiteration, Analyst Ratings
Biohaven Reports Pricing Of Public Offering Of 5.609M Of Its Common Shares At $41 Per Share
18 Apr 24
News, Offerings
Biohaven Announces $200M Public Offering Of Common Shares
17 Apr 24
News, Offerings
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Reported Saturday, Biohaven Showcased Innovative Neuroscience Portfolio With 20 Presentations At The 2024 AAN Annual Meeting
15 Apr 24
News
Cantor Fitzgerald Reiterates Overweight on Biohaven
10 Apr 24
News, Reiteration, Analyst Ratings
RBC Capital Reiterates Outperform on Biohaven, Maintains $61 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
27 Mar 24
Biotech, Earnings, News, Guidance, Health Care, Movers, General
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
26 Mar 24
Biotech, Large Cap, News, Health Care, Movers, Trading Ideas, General
HC Wainwright & Co. Maintains Buy on Biohaven, Raises Price Target to $63
4 Mar 24
News, Price Target, Analyst Ratings
RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $61
1 Mar 24
News, Price Target, Analyst Ratings
TD Cowen Maintains Outperform on Biohaven, Raises Price Target to $55
1 Mar 24
News, Price Target, Analyst Ratings
Biohaven Q4 EPS $(1.61) Down From $(1.27) YoY
29 Feb 24
Earnings, News
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
16 Feb 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Initiation, Analyst Ratings, Trading Ideas, General
RBC Capital Initiates Coverage On Biohaven with Outperform Rating, Announces Price Target of $62
16 Feb 24
News, Price Target, Initiation, Analyst Ratings
UBS Initiates Coverage On Biohaven with Buy Rating, Announces Price Target of $59
6 Feb 24
News, Price Target, Initiation, Analyst Ratings
Press releases
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
22 Apr 24
Offerings, Press Releases
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
18 Apr 24
Offerings, Press Releases
Biohaven Announces Proposed Public Offering of Common Shares
17 Apr 24
Offerings, Press Releases
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
13 Apr 24
Press Releases